Perkins John R II 4

4 · Talecris Biotherapeutics Holdings Corp. · Filed Sep 3, 2010

Form 4

Period: 2010-09-01

Sr.VP & GM, Portfolio & US Bus

Transactions

Sale
Common Stock
2010-09-01$22.30/sh−10,200$227,460→ 47,494 total
Exercise/Conversion
Common Stock
2010-09-02$11.00/sh+168,704$1,855,744→ 216,198 total
Exercise/Conversion
Options (right to buy)
2010-09-01$11.00/sh−8,100$89,100→ 44,620 total
Exercise: $11.00From: 2009-04-01Exp: 2018-04-01→ Common Stock (8,100 underlying)
Exercise/Conversion
Common Stock
2010-09-02$11.00/sh+44,620$490,820→ 260,818 total
Exercise/Conversion
Options (right to buy)
2010-09-02$11.00/sh−168,704$1,855,744→ 42,176 total
Exercise: $11.00From: 2006-12-06Exp: 2016-12-06→ Common Stock (168,704 underlying)
Exercise/Conversion
Common Stock
2010-09-01$11.00/sh+8,100$89,100→ 57,694 total
Exercise/Conversion
Options (right to buy)
2010-09-02$11.00/sh−44,620$490,820→ 0 total
Exercise: $11.00From: 2009-04-01Exp: 2018-04-01→ Common Stock (44,620 underlying)

Footnotes (3)

[F1]The transaction reported was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2010.
[F2]The number of shares reported includes restricted share units representing the right to receive 5,921 shares of the Issuers common stock that will vest in three equal annual installments beginning April 1, 2011, as detailed in a restricted share unit award agreement by and between the Issuer and the Reporting Person, dated as of September 30, 2009.
[F3]The option is fully vested and immediately exercisable.

Documents

1 file